A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Varlilumab Patients With Advanced Melanoma

Trial Profile

A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Varlilumab Patients With Advanced Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Glembatumumab vedotin (Primary) ; Varlilumab (Primary) ; Nivolumab; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 06 Jun 2017 Results (n=62) assessing safety and efficacy of GV monotherapy, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Results published in a Celldex Therapeutics media release.
    • 05 Jun 2017 According to a Celldex Therapeutics media release, results were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top